% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Cheteh:125342,
author = {E. H. Cheteh and M. Augsten$^*$ and H. Rundqvist and J.
Bianchi and V. Sarne and L. Egevad and V. J. Bykov and A.
Östman and K. G. Wiman},
title = {{H}uman cancer-associated fibroblasts enhance glutathione
levels and antagonize drug-induced prostate cancer cell
death.},
journal = {Cell death $\&$ disease},
volume = {8},
number = {6},
issn = {2041-4889},
address = {London [u.a.]},
publisher = {Nature Publishing Group},
reportid = {DKFZ-2017-01475},
pages = {e2848 -},
year = {2017},
abstract = {Drug resistance is a major problem in cancer therapy. A
growing body of evidence demonstrates that the tumor
microenvironment, including cancer-associated fibroblasts
(CAFs), can modulate drug sensitivity in tumor cells. We
examined the effect of primary human CAFs on p53 induction
and cell viability in prostate cancer cells on treatment
with chemotherapeutic drugs. Co-culture with prostate CAFs
or CAF-conditioned medium attenuated DNA damage and the p53
response to chemotherapeutic drugs and enhanced prostate
cancer cell survival. CAF-conditioned medium inhibited the
accumulation of doxorubicin, but not taxol, in prostate
cancer cells in a manner that was associated with increased
cancer cell glutathione levels. A low molecular weight
fraction (<3 kDa) of CAF-conditioned medium had the same
effect. CAF-conditioned medium also inhibited induction of
reactive oxygen species (ROS) in both doxorubicin- and
taxol-treated cancer cells. Our findings suggest that CAFs
can enhance drug resistance in cancer cells by inhibiting
drug accumulation and counteracting drug-induced oxidative
stress. This protective mechanism may represent a novel
therapeutic target in cancer.},
cin = {A190},
ddc = {570},
cid = {I:(DE-He78)A190-20160331},
pnm = {311 - Signalling pathways, cell and tumor biology
(POF3-311)},
pid = {G:(DE-HGF)POF3-311},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:28569790},
pmc = {pmc:PMC5520886},
doi = {10.1038/cddis.2017.225},
url = {https://inrepo02.dkfz.de/record/125342},
}